bio investment rule #1 - research is the key, page-9

Hi Chook,

The following links should provide you with an excellent starting point. Keep in mind you will not find OBJ's name in print whilst strict provisions remain however references to our technologies are quite obvious now.

OBJ is the first company in the world to develop low cost micro-array film technology that utilises diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

You will find a vast amount of information on Vertex Pharma's website, as I posted only a sample of yesterday which provides more sound evidence of OBJ's substantial 7 year collaboration programs and clinical trials with a number of global Pharma's and FMCG's.

Phaselll clinical trials are providing some very exciting data and if my understanding with some of what I've already seen is correct, OBJ's technology might be attracting some worldwide publicity very soon.

If I'm reading some of the data sheets for one of the trials correctly, the term "cure" has been described in one of these developments within an unmet disease market.

Click here for pubmed source

Click here for pubmed source

Click here for pubmed source

Click here for pubmed source

Click here for Vertex Pharmaceuticals website

Click here for pubmed source

I'm a little concerned that too much information shared over a public forum might be detrimental to confidentiality provisions. Any thoughts on this guys?

I would not particularly want OBJ to request a long drawn out suspension from trading until further agreements with said companies have been finalized